Track CRISPR Therapeutics AG — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

CRISPR Therapeutics AG CRSP · Stock Open CRISPR Therapeutics AG in new tab

42.24 USD
EPS
-4.73
P/B
2.69
ROE
-25.60
Beta
1.90
Target Price
85.42 USD
Loading chart...
Key Metrics
Earnings dateFeb. 16, 2027
EPS-4.73
Book Value17.02
Price to Book2.69
Debt/Equity47.32
% Insiders5.316%
Growth
Revenue Growth13.25%
Estimates
Forward P/E-12.46
Forward EPS-3.67
Target Mean Price85.42

DCF valuation

Model fair value for CRISPR Therapeutics AG (CRSP)
Result
Sign in to run the valuation for CRSP.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
19 analysts · consensus Buy · mean target 85.42 USD (low 44.00, high 291.00) · as of 12 Nov 2026
Low 44.00
Mean 85.42
High 291.00
Price 42.24
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

CRISPR Therapeutics AG Logo CRISPR Therapeutics AG Analysis (CRSP)

Switzerland Health Care Official Website Stock

Is CRISPR Therapeutics AG a good investment? CRISPR Therapeutics AG (CRSP) is currently trading at 42.24 USD. Market analysts have a consensus price target of 85.42 USD. This suggests a potential upside from current levels.

Earnings Schedule: CRISPR Therapeutics AG is expected to release its next earnings report on Feb. 16, 2027. The market consensus estimate for Forward EPS is -3.67.

Investor FAQ

Does CRISPR Therapeutics AG pay a dividend?

No, it does not currently pay a dividend.

What asset class is CRISPR Therapeutics AG?

CRISPR Therapeutics AG is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 16, 2027. The company currently has a trailing EPS of -4.73.

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting allogeneic chimeric antigen receptor T cell for autoimmune indications and oncology. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Exchange Ticker
1CG.F
NMS (United States) CRSP
LSE (United Kingdom) 0VRQ.L
MEX (Mexico) CRSPN.MX
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion